<?xml version="1.0" encoding="UTF-8"?><law><structure><unit label="title" identifier="XXV" order_by="25">BUSINESS AND FINANCIAL INSTITUTIONS</unit><unit label="chapter" identifier="" order_by=""></unit></structure><section_number>304.17A-135</section_number><catch_line>Coverage for treatment of breast cancer. </catch_line><order_by>17A-135</order_by><text><section prefix="1">Health benefit plans which provide benefits for treatment of breast cancer by chemotherapy shall also provide coverage for treatment of breast cancer by high-dose chemotherapy with autologous bone marrow transplantation or stem cell transplantation. </section><section prefix="2">The administration of high-dose chemotherapy with autologous bone marrow transplantation or stem cell transplantation shall only be covered when performed in institutions that comply with the guidelines of the American Society for Blood and Marrow Transplantation or the International Society of Hematotherapy and Graft Engineering, whichever has the higher standard. </section><section prefix="3">Treatment of breast cancer by high-dose chemotherapy with autologous bone marrow transplantation or stem cell transplantation shall not be considered experimental or investigational. Coverage for transplantation under this section shall not be subject to any greater coinsurance or copayment than that applicable to any other coverage provided by the health plan. </section></text><history> Created 1996 Ky. Acts ch. 114, sec. 5, effective March 28, 1996. </history><metadata><effective> March 28, 1996 </effective><pdf-author>ganesan_m</pdf-author><pdf-creation-date>2015-07-02</pdf-creation-date><pdf-download-date>2016-03-18 12:16:05</pdf-download-date><original-link>http://www.lrc.ky.gov/statutes/statute.aspx?id=17370</original-link></metadata><tags><tag>computer-parsed</tag><tag>unverified</tag></tags></law>